Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SURMOUNT-2

SURMOUNT-2

Tirzepatide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
t2d
Official title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2021-03 → 2023-03
Participants
938
Duration
72 weeks
Registry
NCT04657003

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
tirzepatide 15 mgt2d72938−15.7 % vs −3.3 %
Δ −12.4 pp
−14.7 % vs −3.2 %
Δ −11.5 pp
−2.1 vs −0.57.4 vs 3.813.8 vs 14.921.9 vs 6.313.2 vs 3.28.7 vs 7.3—verified
tirzepatide 10 mgt2d72938−13.4 % vs −3.3 %
Δ −10.1 pp
−12.8 % vs −3.2 %
Δ −9.6 pp
−2.1 vs −0.53.8 vs 3.89.3 vs 14.920.2 vs 6.310.9 vs 3.25.8 vs 7.3—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (11)
  • tirzepatide 15 mg · nausea · Table 3
    | Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
  • tirzepatide 15 mg · vomiting · Table 3
    | Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
  • tirzepatide 15 mg · disc_any · Figure 1 (trial profile)
    | 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
  • tirzepatide 15 mg · sae · Table 3
    | Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
  • tirzepatide 15 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
    | Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |
  • tirzepatide 15 mg · hba1c · Table 2 + Results
    | Change in HbA₁c, % | -2·07 (0·06) | -2·08 (0·07) | -0·51 (0·07) | ETD -1·55 (-1·74, -1·37); p<0·0001 | ETD -1·57 (-1·76, -1·37); p<0·0001 |
  • tirzepatide 10 mg · nausea · Table 3
    | Nausea | 63 (20·2) | 68 (21·9) | 20 (6·3) |
  • tirzepatide 10 mg · vomiting · Table 3
    | Vomiting | 34 (10·9) | 41 (13·2) | 10 (3·2) |
  • tirzepatide 10 mg · disc_any · Figure 1 (trial profile)
    | 29 (9·3%) discontinued study treatment | 43 (13·8%) discontinued study treatment | 47 (14·9%) discontinued study treatment |
  • tirzepatide 10 mg · sae · Table 3
    | Serious adverse events\* | 18 (5·8) | 27 (8·7) | 23 (7·3) |
  • tirzepatide 10 mg · ae_dc · Table 3 (columns: 10 mg, 15 mg, placebo)
    | Adverse events leading to discontinuation of study drug† | 12 (3·8) | 23 (7·4) | 12 (3·8) |

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SURMOUNT-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.